ACRX News and Press, AcelRx Pharmaceuticals Inc.

2024-01-09 09:10:23 ET More on AcelRx Pharmaceuticals Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals Historical earnings data for AcelRx Pharmaceuticals Financial information for AcelRx Pharmaceuticals For further details see: AcelRx announ...

AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...

2023-12-14 11:38:55 ET More on AcelRx Pharmaceuticals Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals Historical earnings data for AcelRx Pharmaceuticals Financial information for AcelRx Pharmaceuticals For further details see: AcelRx Pharma...

AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...

2023-11-22 16:45:12 ET AcelRx Pharmaceuticals ( NASDAQ: ACRX ) on Wednesday filed a prospectus for a mixed securities shelf offering of up to $150M. This prospectus is not an offer to sell these securities. SEC Filing For further details see: AcelRx Pharmaceu...

2023-11-09 00:27:10 ET AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Conference Call November 08, 2023, 16:30 ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - Chief Medical Officer and Co-Founder Conference Call Particip...

2023-11-08 16:10:52 ET More on AcelRx Pharmaceuticals AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript AcelRx upgraded at HC Wainwright on likely authorization of anticoagulant Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals ...

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

AcelRx Pharmaceuticals Inc. (ACRX) is expected to report $-0.29 for Q3 2023